Physician profile
Sade Wright
NPI 1073107256
$2,402.74
in general payments reported to CMS, 2019-2025
26 companies · $1,748 in 2025
The $1,748 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $654 · 2025: $1,748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,402.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $265.81 | 2024-2025 | Watchman Flx |
| Novo Nordisk INC | $261.69 | 2024-2025 | Wegovy, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $218.81 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $177.83 | 2024-2025 | Lifevest |
| Pfizer INC. | $155.45 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $154.66 | 2024-2025 | Verquvo, Dificid, Prevymis |
| Astrazeneca Pharmaceuticals Lp | $149.16 | 2024-2025 | Wainua, Farxiga |
| Kestra Medical Technology Services, INC. | $139.92 | 2025 | Assure Wcd |
| Actelion Pharmaceuticals US, INC. | $135.72 | 2024-2025 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.71 | 2024-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $93.89 | 2025 | |
| Scpharmaceuticals INC. | $86.78 | 2024-2025 | |
| Amgen INC. | $56.80 | 2024-2025 | Repatha, Repatha |
| Shockwave Medical, INC | $53.32 | 2025 | |
| Janssen Pharmaceuticals, INC | $47.46 | 2024 | Xarelto |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $43.18 | 2025 | |
| Lilly USA, LLC | $42.77 | 2025 | Zepbound, Mounjaro |
| Bridgebio Pharma, INC. | $31.40 | 2025 | Attruby |
| Alnylam Pharmaceuticals INC. | $29.89 | 2025 | Amvuttra |
| E.R. Squibb & Sons, L.L.C. | $27.04 | 2024 | Eliquis |
| Inspire Medical Systems, INC. | $25.82 | 2024 | Inspire |
| Tactile Systems Technology INC | $17.55 | 2024 | Entre Plus, Flexitouch Plus |
| Esperion Therapeutics, INC. | $16.81 | 2025 | Nexletol |
| Chiesi USA, INC. | $15.64 | 2024 | Kengreal, Cleviprex |
| Idorsia Pharmaceuticals US INC | $14.32 | 2025 | Tryvio |
| Lexicon Pharmaceuticals, INC. | $14.31 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sade Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.